Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01330
|
|||||
| Drug Name |
Clofarabine
|
|||||
| Synonyms |
(2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; 2-Cl-2'-F-araA; 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine; 3S211048; CAFdA; CFB; Cl-F-Ara-A; Clofarabina; Clofarabine (USAN/INN); Clofarabine [USAN]; Clofarabinum; Clofarex; Clolar; Clolar (TN); Clolar, Evoltra, Clofarabine; Evoltra; Evoltra (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Acute lymphoblastic leukemia [ICD11:2B33.0] | Approved | [1] | |||
| Juvenile myelomonocytic leukemia [ICD11:2A42] | Approved | [1] | ||||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C10H11ClFN5O3
|
|||||
| Canonical SMILES |
C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N
|
|||||
| InChI |
InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1
|
|||||
| InChIKey |
WDDPHFBMKLOVOX-AYQXTPAHSA-N
|
|||||
| CAS Number |
CAS 123318-82-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 303.68 | Topological Polar Surface Area | 119 | ||
| Heavy Atom Count | 20 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
0.9
|
|||||
| PubChem CID | ||||||
| PubChem SID |
8149071
,10238376
,10317422
,12014412
,14800615
,14800616
,29300120
,46504968
,47205855
,50027432
,56459308
,57339361
,71821361
,77716344
,81092867
,92309003
,92719465
,93608050
,99437031
,99444025
,103707445
,104407717
,109610765
,118048878
,124757091
,125163895
,126584329
,126620778
,126652234
,126671067
,129564367
,134223319
,134338128
,135073562
,135698306
,136920392
,136946661
,136949087
,137005624
,141857409
,143493352
,144115841
,144205735
,152058774
,152237732
,152258941
,160647786
,160963976
,162011506
,162176704
|
|||||
| ChEBI ID |
CHEBI:681569
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| CNT3 | Transporter Info | Concentrative Na(+)-nucleoside cotransporter 3 | Substrate | [3] | ||
| ENT1 | Transporter Info | Equilibrative nucleoside transporter 1 | Substrate | [3] | ||
| ENT2 | Transporter Info | Equilibrative nucleoside transporter 2 | Substrate | [3] | ||
| References | ||||||
| 1 | Clofarabine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102. | |||||
| 3 | Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.